Name | sucralose |
---|---|
Synonyms |
(2R,3R,4R,5R,6R)-2-{[(2R,3S,4S,5S)-2,5-Bis(chloromethyl)-3,4-dihydroxytetrahydro-2-furanyl]oxy}-5-chloro-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diol
1',4,6'-Trichlorogalactosucrose 1,6-Dichloro-1,6-dideoxy-β-D-fructofuranosyl 4-chloro-4-deoxy-α-D-galactopyranoside a-D-galactopyranoside, 1,6-dichloro-1,6-dideoxy-b-D-fructofuranosyl 4-chloro-4-deoxy- trichlorosucrose (2R,3R,4R,5R,6R)-2-[(2R,3S,4S,5S)-2,5-bis(chloromethyl)-3,4-dihydroxyoxolan-2-yl]oxy-5-chloro-6-(hydroxymethyl)oxane-3,4-diol MFCD03648615 1,6-dichloro-1,6-dideoxy-b-D-fructofuranosyl 4-chloro-4-deoxy-a-D-galactopyranoside Sucralose EINECS 259-952-2 1,6-Dichlor-1,6-dideoxy-β-D-fructofuranosyl-4-chlor-4-deoxy-α-D-galactopyranoside 4,1',6'-Trichloro-4,1',6'-trideoxygalacto-sucrose 1,6-Dichloro-1,6-dideoxy-b-D-fructofuranosyl-4-chloro-4-deoxy-a-D-galactopyranoside splenda α-D-Galactopyranoside, 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl 4-chloro-4-deoxy- UNII-96K6UQ3ZD4 |
Description | Sucralose is an intense organochlorine artificial sweetener. |
---|---|
Related Catalog | |
In Vivo | The results show that Sucralose induces significant increased incidence of all hematopoietic neoplasias in male mice exposed to 2,000 (p≤0.01), and 16,000 ppm (p≤0.01), with a significant dose-related relationship (p≤0.01). Microscopically, most of the neoplasias among male mice treated with Sucralose at 2,000 to 16,000 ppm are leukemias involving lungs, liver, spleen, lymph nodes, and bone marrow with diffuse permeation of vessels and extensive infiltration of adjacent tissues[1]. |
Animal Admin | Sucralose is pulverized in a standard pelleted diet at concentrations 0, 500, 2,000, 8,000, and 16,000 ppm and is administered to five groups of male (n=117, 114, 90, 66, and 70, respectively) and five groups female (n=102, 105, 60, 65, and 64, respectively) Swiss mice from the 12th day of fetal life until death[1]. |
References |
Density | 1.7±0.1 g/cm3 |
---|---|
Boiling Point | 669.4±55.0 °C at 760 mmHg |
Melting Point | 125.5ºC |
Molecular Formula | C12H19Cl3O8 |
Molecular Weight | 397.634 |
Flash Point | 358.7±31.5 °C |
Exact Mass | 396.014557 |
PSA | 128.84000 |
LogP | 0.68 |
Vapour Pressure | 0.0±4.6 mmHg at 25°C |
Index of Refraction | 1.604 |
Storage condition | Hygroscopic, -20°C Freezer, Under Inert Atmosphere |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
---|---|
Hazard Codes | Xi: Irritant; |
Risk Phrases | R36/37/38 |
Safety Phrases | 26-37/39 |
RIDADR | NONH for all modes of transport |
RTECS | LW5440140 |
HS Code | 2932999099 |
~96% 56038-13-2 |
Literature: Wu, Jun Jing; Wu, Guang Li; Cai, Qing Hai; Xinyu, Shou; Li, Zi Wen; Liu, Shang; Wang, Man Tang Patent: US2008/58508 A1, 2008 ; Location in patent: Page/Page column 3 ; |
~85% 56038-13-2 |
Literature: EMCURE PHARMACEUTICALS LIMITED Patent: WO2007/96726 A2, 2007 ; Location in patent: Page/Page column 32 ; |
~70% 56038-13-2 |
Literature: TATE and LYLE TECHNOLOGY LIMITED; WILEY, James, Edwin; JABER, Mohamad, R. Patent: WO2010/151489 A1, 2010 ; Location in patent: Page/Page column 14 ; |
~48% 56038-13-2 |
Literature: PHARMED MEDICARE PVT. LTD. Patent: US2009/118493 A1, 2009 ; Location in patent: Page/Page column 3 ; |
~% 56038-13-2 |
Literature: US2010/56773 A1, ; Page/Page column 2 ; |
~% 56038-13-2 |
Literature: US2010/160625 A1, ; Page/Page column 2 ; |
~%
Detail
|
Literature: EP260979 B1, ; |
~% 56038-13-2 |
Literature: US2011/64812 A1, ; |
Precursor 9 | |
---|---|
DownStream 0 |
HS Code | 2932999099 |
---|---|
Summary | 2932999099. other heterocyclic compounds with oxygen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |